- Edwards Lifesciences (EW) and Medtronic (MDT) settle their patent disputes regarding transcatheter heart valves. They agree to dismiss all pending cases and appeals in courts and patent offices worldwide and not litigate patent disputes between them in the field of transcatheter valves for the duration of the eight-year term of the settlement.
- Under the terms of the agreement, Medtronic will make a one-time payment to Edwards of $750M and make quarterly royalty payments through April 2022 based on a percentage of Medtronic CoreValve sales subject to a minimum of $40M/year.
- Edwards will contribute $50M from the settlement to its Every Heartbeat Matters philanthropic program.
From other sites
at Zacks.com (Mar 27, 2015)
Edwards Lifesciences : ' CEO Addresses Senate Committee On Preserving And Strengthening Medical Device Innovation In The U.S.at 4-traders.com (Mar 24, 2015)
at Zacks.com (Mar 18, 2015)
at Investor's Business Daily (Feb 4, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs